{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:21:31Z","timestamp":1747207291146,"version":"3.40.5"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract::<\/jats:title>\n<jats:p>Mexiletine is an antiarrhythmic drug belonging to IB class, acting as sodium channel\nblocker. Besides its well-known activity on arrhythmias, its usefulness in the treatment of\nmyotonia, myotonic dystrophy and amyotrophic lateral sclerosis is now widely recognized.\nNevertheless, it has been retired from the market in several countries because of its undesired\neffects. Thus, several papers were reported in the last years about analogues and homologues\nof mexiletine being endowed with a wider therapeutic ratio and a more selectivity of action.\nSome of them showed sodium channel blocking activity higher than the parent compound. It\nis noteworthy that mexiletine is used in therapy as a racemate even though a difference in the\nactivities of the two enantiomers was widely demonstrated, with (\u2013)-(R)-enantiomer being\nmore active: this finding led several research groups to study mexiletine and its analogues and\nhomologues in their optically active forms. This review summarizes the different synthetic\nroutes used to obtain these compounds. They could represent an interesting starting point to\nnew mexiletine-like compounds without common side effects related to the use of mexiletine.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200504080530","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T10:20:57Z","timestamp":1588587657000},"page":"1535-1548","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-4706","authenticated-orcid":true,"given":"Alessia","family":"Catalano","sequence":"first","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, via Orabona 4, 70126 Bari,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-750X","authenticated-orcid":true,"given":"Carlo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, via Orabona 4, 70126 Bari,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2248-9292","authenticated-orcid":true,"given":"Alessia","family":"Carocci","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, via Orabona 4, 70126 Bari,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.2174\/0929867323666160517120234","volume":"23","author":"Catalano A.","year":"2016","unstructured":"Catalano A.; Carocci A.; Antiarrhythmic mexiletine: a review on synthetic routes to racemic and homochiral mexiletine and its enantioseparation. Curr Med Chem 2016,23(29),3227-3244","journal-title":"Curr Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.2174\/0929867325666180327104320","volume":"25","author":"Carocci A.","year":"2018","unstructured":"Carocci A.; Corbo F.; Lentini G.; Cavalluzzi M.M.; Franchini C.; Catalano A.; A focus on the synthesis and pharmacokinetics of tocainide and its analogues. Curr Med Chem 2018,25(42),5822-5834","journal-title":"Curr Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/0002-9149(81)90191-0","volume":"47","author":"Podrid P.J.","year":"1981","unstructured":"Podrid P.J.; Lown B.; Mexiletine for ventricular arrhythmias. Am J Cardiol 1981,47(4),895-902","journal-title":"Am J Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacep.2015.05.008","volume":"1","author":"Badri M.","year":"2015","unstructured":"Badri M.; Patel A.; Patel C.; Liu G.; Goldstein M.; Robinson V.M.; Xue X.; Yang L.; Kowey P.R.; Yan G.X.; Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures. JACC Clin Electrophysiol 2015,1(4),315-322","journal-title":"JACC Clin Electrophysiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s13311-018-00678-0","volume":"15","author":"Phillips L.","year":"2018","unstructured":"Phillips L.; Trivedi J.R.; Skeletal muscle channelopathies. Neurotherapeutics 2018,15(4),954-965","journal-title":"Neurotherapeutics"},{"key":"ref=6","first-page":"46","volume":"15","author":"Hahn C.","year":"2016","unstructured":"Hahn C.; Salajegheh M.K.; Myotonic disorders: a review article. Iran J Neurol 2016,15(1),46-53","journal-title":"Iran J Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/ejhpharm-2015-000839","volume":"23","author":"D\u2019Mello S.","year":"2016","unstructured":"D\u2019Mello S.; Shum L.; A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia. Eur J Hosp Pharm Sci Pract 2016,23(6),359-363","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/papr.12054","volume":"14","author":"Snedecor S.J.","year":"2014","unstructured":"Snedecor S.J.; Sudharshan L.; Cappelleri J.C.; Sadosky A.; Mehta S.; Botteman M.; Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014,14(2),167-184","journal-title":"Pain Pract"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/13543771003774118","volume":"20","author":"Zuliani V.","year":"2010","unstructured":"Zuliani V.; Rivara M.; Fantini M.; Costantino G.; Sodium channel blockers for neuropathic pain. Expert Opin Ther Pat 2010,20(6),755-779","journal-title":"Expert Opin Ther Pat"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCEP.113.000092","volume":"6","author":"Gao Y.","year":"2013","unstructured":"Gao Y.; Xue X.; Hu D.; Liu W.; Yuan Y.; Sun H.; Li L.; Timothy K.W.; Zhang L.; Li C.; Yan G-X.; Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome. Circ Arrhythm Electrophysiol 2013,6(3),614-622","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/14737175.2016.1197774","volume":"16","author":"Noto Y.","year":"2016","unstructured":"Noto Y.; Shibuya K.; Vucic S.; Kiernan M.C.; Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Rev Neurother 2016,16(10),1147-1154","journal-title":"Expert Rev Neurother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mus.26117","volume":"58","author":"Oskarsson B.","year":"2018","unstructured":"Oskarsson B.; Moore D.; Mozaffar T.; Ravits J.; Wiedau-Pazos M.; Parziale N.; Joyce N.C.; Mandeville R.; Goyal N.; Cudkowicz M.E.; Weiss M.; Miller R.G.; McDonald C.M.; Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve 2018,58(1),42-48","journal-title":"Muscle Nerve"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/chir.20240","volume":"18","author":"Bruno C.","year":"2006","unstructured":"Bruno C.; Carocci A.; Catalano A.; Cavalluzzi M.M.; Corbo F.; Franchini C.; Lentini G.; Tortorella V.; Facile, alternative route to lubeluzole, its enantiomer, and the racemate. Chirality 2006,18(4),227-231","journal-title":"Chirality"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.nurt.2007.01.013","volume":"4","author":"Camerino D.C.","year":"2007","unstructured":"Camerino D.C.; Tricarico D.; Desaphy J-F.; Ion channel pharmacology. Neurotherapeutics 2007,4(2),184-198","journal-title":"Neurotherapeutics"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coph.2013.11.014","volume":"15","author":"Remme C.A.","year":"2014","unstructured":"Remme C.A.; Wilde A.A.M.; Targeting sodium channels in cardiac arrhythmia. Curr Opin Pharmacol 2014,15,53-60","journal-title":"Curr Opin Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jmg.2003.012153","volume":"41","author":"Yang Y.","year":"2004","unstructured":"Yang Y.; Wang Y.; Li S.; Xu Z.; Li H.; Ma L.; Fan J.; Bu D.; Liu B.; Fan Z.; Wu G.; Jin J.; Ding B.; Zhu X.; Shen Y.; Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004,41(3),171-174","journal-title":"J Med Genet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1235.e5","DOI":"10.1016\/j.ajem.2010.08.027","volume":"29","author":"Ak\u0131nc\u0131 E.","year":"2011","unstructured":"Ak\u0131nc\u0131 E.; Y\u00fczba\u015f\u0131oglu Y.; Co\u015fkun F.; Hemodialysis as an alternative treatment of mexiletine intoxication. Am J Emerg Med 2011,29(9),1235.e5-1235.e6","journal-title":"Am J Emerg Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ncpneuro0239","volume":"2","author":"Chrestian N.","year":"2006","unstructured":"Chrestian N.; Puymirat J.; Bouchard J-P.; Dupr\u00e9 N.; Myotonia congenita--a cause of muscle weakness and stiffness. Nat Clin Pract Neurol 2006,2(7),393-399","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/brain\/aws225","volume":"135","author":"Eijkelkamp N.","year":"2012","unstructured":"Eijkelkamp N.; Linley J.E.; Baker M.D.; Minett M.S.; Cregg R.; Werdehausen R.; Rugiero F.; Wood J.N.; Neurological perspectives on voltage-gated sodium channels. Brain 2012,135(Pt 9),2585-2612","journal-title":"Brain"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"Finnerup N.B.","year":"2015","unstructured":"Finnerup N.B.; Attal N.; Haroutounian S.; McNicol E.; Baron R.; Dworkin R.H.; Gilron I.; Haanp\u00e4\u00e4 M.; Hansson P.; Jensen T.S.; Kamerman P.R.; Lund K.; Moore A.; Raja S.N.; Rice A.S.; Rowbotham M.; Sena E.; Siddall P.; Smith B.H.; Wallace M.; Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015,14(2),162-173","journal-title":"Lancet Neurol"},{"key":"ref=21","author":"Cashman J.R.","year":"2017","unstructured":"Cashman J.R.; Ryan D.J.; Okolotowicz K.; Compounds as inhibitors of sodium channels. WO Patent 2017\/210371\/A2 2017","journal-title":"WO Patent 2017\/210371\/A2"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/chir.10307","volume":"16","author":"Catalano A.","year":"2004","unstructured":"Catalano A.; Carocci A.; Fracchiolla G.; Franchini C.; Lentini G.; Tortorella V.; De Luca A.; De Bellis M.; Desaphy J-F.; Conte Camerino D.; Stereospecific synthesis of \u201cpara-hydroxymexiletine\u201d and sodium channel blocking activity evaluation. Chirality 2004,16(2),72-78","journal-title":"Chirality"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.bjp.0706867","volume":"149","author":"De Bellis M.","year":"2006","unstructured":"De Bellis M.; De Luca A.; Rana F.; Cavalluzzi M.M.; Catalano A.; Lentini G.; Franchini C.; Tortorella V.; Conte Camerino D.; Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents. Br J Pharmacol 2006,149(3),300-310","journal-title":"Br J Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.tetasy.2007.10.002","volume":"18","author":"Cavalluzzi M.M.","year":"2007","unstructured":"Cavalluzzi M.M.; Catalano A.; Bruno C.; Lovece A.; Carocci A.; Corbo F.; Franchini C.; Lentini G.; Tortorella V.; Synthesis of (R)-, (S)-, and (RS)-hydroxymethylmexiletine, one of the major metabolites of mexiletine. Tetrahedron Asymmetry 2007,18(20),2409-2417","journal-title":"Tetrahedron Asymmetry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.tetasy.2009.08.002","volume":"20","author":"Cavalluzzi M.M.","year":"2009","unstructured":"Cavalluzzi M.M.; Bruno C.; Lentini G.; Lovece A.; Catalano A.; Carocci A.; Franchini C.; One-step synthesis of homochiral O-aryl and O-heteroaryl mandelic acids and their use as efficient 1H NMR chiral solvating agents. Tetrahed. Asym 2009,20(17),1984-1991","journal-title":"Asym"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1021\/jm201197z","volume":"55","author":"Catalano A.","year":"2012","unstructured":"Catalano A.; Desaphy J-F.; Lentini G.; Carocci A.; Di Mola A.; Bruno C.; Carbonara R.; De Palma A.; Budriesi R.; Ghelardini C.; Perrone M.G.; Colabufo N.A.; Conte Camerino D.; Franchini C.; Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels. J Med Chem 2012,55(3),1418-1422","journal-title":"J Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1872312811206020124","volume":"6","author":"Catalano A.","year":"2012","unstructured":"Catalano A.; Carocci A.; Lentini G.; Defrenza I.; Cavalluzzi M.M.; Franchini C.; An improved synthesis of m-hydroxymexiletine, a potent mexiletine metabolite. Drug Metab Lett 2012,6(2),124-128","journal-title":"Drug Metab Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/1872312811206030005","volume":"6","author":"Catalano A.","year":"2012","unstructured":"Catalano A.; Carocci A.; Lentini G.; Defrenza I.; Bruno C.; Franchini C.; Stereospecific synthesis of m-Hydroxymexiletine enantiomers. Drug Metab Lett 2012,6(3),182-186","journal-title":"Drug Metab Lett"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fphar.2012.00017","volume":"3","author":"Desaphy J-F.","year":"2012","unstructured":"Desaphy J-F.; Dipalma A.; Costanza T.; Carbonara R.; Dinardo M.M.; Catalano A.; Carocci A.; Lentini G.; Franchini C.; Camerino D.C.; Molecular insight into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine. Front Pharmacol 2012,3,17","journal-title":"Front Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ardp.200900218","volume":"343","author":"Catalano A.","year":"2010","unstructured":"Catalano A.; Carocci A.; Cavalluzzi M.M.; Di Mola A.; Lentini G.; Lovece A.; Dipalma A.; Costanza T.; Desaphy J.F.; Conte Camerino D.; Franchini C.; Hydroxylated analogs of mexiletine as tools for structural-requirements investigation of the sodium channel blocking activity. Arch Pharm (Weinheim) 2010,343(6),325-332","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ejmech.2013.05.008","volume":"65","author":"Catalano A.","year":"2013","unstructured":"Catalano A.; Budriesi R.; Bruno C.; Di Mola A.; Defrenza I.; Cavalluzzi M.M.; Micucci M.; Carocci A.; Franchini C.; Lentini G.; Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers. Eur J Med Chem 2013,65,511-516","journal-title":"Eur J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.2174\/0929867322666150227145412","volume":"22","author":"Catalano A.","year":"2015","unstructured":"Catalano A.; Carocci A.; Sinicropi M.S.; Mexiletine metabolites: a review. Curr Med Chem 2015,22(11),1400-1413","journal-title":"Curr Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.ejmech.2008.01.023","volume":"43","author":"Catalano A.","year":"2008","unstructured":"Catalano A.; Carocci A.; Corbo F.; Franchini C.; Muraglia M.; Scilimati A.; De Bellis M.; De Luca A.; Camerino D.C.; Sinicropi M.S.; Tortorella V.; Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents. Eur J Med Chem 2008,43(11),2535-2540","journal-title":"Eur J Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1021\/jm401864b","volume":"57","author":"Muraglia M.","year":"2014","unstructured":"Muraglia M.; De Bellis M.; Catalano A.; Carocci A.; Franchini C.; Carrieri A.; Fortugno C.; Bertucci C.; Desaphy J.F.; De Luca A.; Conte Camerino D.; Corbo F.; N-aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels. J Med Chem 2014,57(6),2589-2600","journal-title":"J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.nmd.2011.07.001","volume":"22","author":"De Luca A.","year":"2012","unstructured":"De Luca A.; De Bellis M.; Corbo F.; Franchini C.; Muraglia M.; Catalano A.; Carocci A.; Camerino D.C.; Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide. Neuromuscul Disord 2012,22(1),56-65","journal-title":"Neuromuscul Disord"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1021\/jm030865y","volume":"46","author":"Franchini C.","year":"2003","unstructured":"Franchini C.; Carocci A.; Catalano A.; Cavalluzzi M.M.; Corbo F.; Lentini G.; Scilimati A.; Tortorella P.; Camerino D.C.; De Luca A.; Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels. J Med Chem 2003,46(24),5238-5248","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bpj.2012.11.3830","volume":"104","author":"De Bellis M.","year":"2013","unstructured":"De Bellis M.; De Luca A.; Desaphy J-F.; Carbonara R.; Heiny J.A.; Kennedy A.; Carocci A.; Cavalluzzi M.M.; Lentini G.; Franchini C.; Camerino D.C.; Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels. Biophys J 2013,104(2),344-354","journal-title":"Biophys J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.1021\/jo801181d","volume":"73","author":"Huang K.","year":"2008","unstructured":"Huang K.; Ortiz-Marciales M.; Stepanenko V.; De Jes\u00fas M.; Correa W.; A practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel \u03b2-thiophenoxy and pyridyl ethers. J Org Chem 2008,73(17),6928-6931","journal-title":"J Org Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/chir.22318","volume":"26","author":"Jin K.B.","year":"2014","unstructured":"Jin K.B.; Kim H.E.; Hyun M.H.; Liquid chromatographic resolution of mexiletine and its analogs on crown ether-based chiral stationary phases. Chirality 2014,26(5),272-278","journal-title":"Chirality"},{"key":"ref=40","author":"Ortiz-Marciales M.","year":"2011","unstructured":"Ortiz-Marciales M.; Huang K.; Stepanenko V.; De Jesus M.; Correa W.; Method of synthesizing enantiopure mexiletine analogues and novel \u03b2-thiophenoxy and pyridyl ethers. US Patent 8012901 B1 2011","journal-title":"US Patent 8012901 B1"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.ejmech.2008.10.005","volume":"44","author":"Carrieri A.","year":"2009","unstructured":"Carrieri A.; Muraglia M.; Corbo F.; Pacifico C.; 2D- and 3D-QSAR of tocainide and mexiletine analogues acting as Na(v)1.4 channel blockers. Eur J Med Chem 2009,44(4),1477-1485","journal-title":"Eur J Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejmech.2016.05.046","volume":"121","author":"Roselli M.","year":"2016","unstructured":"Roselli M.; Carocci A.; Budriesi R.; Micucci M.; Toma M.; Di Cesare Mannelli L.; Lovece A.; Catalano A.; Cavalluzzi M.M.; Bruno C.; De Palma A.; Contino M.; Perrone M.G.; Colabufo N.A.; Chiarini A.; Franchini C.; Ghelardini C.; Habtemariam S.; Lentini G.; Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues. Eur J Med Chem 2016,121,300-307","journal-title":"Eur J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1016\/S0957-4166(00)00332-3","volume":"11","author":"Carocci A.","year":"2000","unstructured":"Carocci A.; Catalano A.; Corbo F.; Duranti A.; Amoroso R.; Franchini C.; Lentini G.; Tortorella V.; Stereospecific synthesis of mexiletine and related compounds: Mitsunobu versus Williamson reaction. Tetrahed. Asym 2000,11(17),3619-3634","journal-title":"Asym"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/chem.201303541","volume":"20","author":"Talwar D.","year":"2014","unstructured":"Talwar D.; Salguero N. P.; Robertson C. M.; Xiao J.; Primary amines by transfer hydrogenative reductive amination of ketones by using cyclometalated IrIII catalysts. Chemistry\u2013 A Eur J 2014,20(1),245-252","journal-title":"Chemistry\u2013 A Eur J"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1021\/jm060414o","volume":"50","author":"Liu H.","year":"2007","unstructured":"Liu H.; Gao Z.B.; Yao Z.; Zheng S.; Li Y.; Zhu W.; Tan X.; Luo X.; Shen J.; Chen K.; Hu G.Y.; Jiang H.; Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay. J Med Chem 2007,50(1),83-93","journal-title":"J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00210-002-0669-0","volume":"367","author":"De Luca A.","year":"2003","unstructured":"De Luca A.; Talon S.; De Bellis M.; Desaphy J.F.; Franchini C.; Lentini G.; Catalano A.; Corbo F.; Tortorella V.; Conte-Camerino D.; Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile. Naunyn Schmiedebergs Arch Pharmacol 2003,367(3),318-327","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/0929867043456232","volume":"11","author":"M\u00e1tyus P.","year":"2004","unstructured":"M\u00e1tyus P.; Varga I.; Rettegi T.; Simay A.; K\u00e1llay N.; K\u00e1rolyh\u00e1zy L.; Kocsis A.; Varr\u00f3 A.; P\u00e9nzes I.; Papp J.G.; Novel antiarrhythmic compounds with combined class IB and class III mode of action. Curr Med Chem 2004,11(1),61-69","journal-title":"Curr Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/chir.20741","volume":"22","author":"Carocci A.","year":"2010","unstructured":"Carocci A.; Catalano A.; Bruno C.; Lentini G.; Franchini C.; De Bellis M.; De Luca A.; Conte Camerino D.; Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs. Chirality 2010,22(3),299-307","journal-title":"Chirality"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1021\/jm060878m","volume":"50","author":"Vazzana I.","year":"2007","unstructured":"Vazzana I.; Budriesi R.; Terranova E.; Ioan P.; Ugenti M.P.; Tasso B.; Chiarini A.; Sparatore F.; Novel quinolizidinyl derivatives as antiarrhythmic agents. J Med Chem 2007,50(2),334-343","journal-title":"J Med Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1021\/jm100298d","volume":"53","author":"Tasso B.","year":"2010","unstructured":"Tasso B.; Budriesi R.; Vazzana I.; Ioan P.; Micucci M.; Novelli F.; Tonelli M.; Sparatore A.; Chiarini A.; Sparatore F.; Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation. J Med Chem 2010,53(12),4668-4677","journal-title":"J Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fphar.2017.00907","volume":"8","author":"De Bellis M.","year":"2018","unstructured":"De Bellis M.; Sanarica F.; Carocci A.; Lentini G.; Pierno S.; Rolland J.F.; Conte Camerino D.; De Luca A.; Dual action of mexiletine and its pyrroline derivatives as skeletal muscle sodium channel blockers and anti-oxidant compounds: toward novel therapeutic potential. Front Pharmacol 2018,8,907","journal-title":"Front Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0006-8993(02)02275-8","volume":"932","author":"Williams A.J.","year":"2002","unstructured":"Williams A.J.; Tortella F.C.; Neuroprotective effects of the sodium channel blocker RS100642 and attenuation of ischemia-induced brain seizures in the rat. Brain Res 2002,932(1-2),45-55","journal-title":"Brain Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1742-7843.2012.00880.x","volume":"111","author":"Batcioglu K.","year":"2012","unstructured":"Batcioglu K.; Uyumlu A.B.; Satilmis B.; Yildirim B.; Yucel N.; Demirtas H.; Onkal R.; Guzel R.M.; Djamgoz M.B.; Oxidative stress in the in vivo DMBA rat model of breast cancer: suppression by a voltage-gated sodium channel inhibitor (RS100642). Basic Clin Pharmacol Toxicol 2012,111(2),137-141","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5114\/aoms.2017.72550","volume":"15","author":"Kamisli S.","year":"2019","unstructured":"Kamisli S.; Basaran C.; Batcioglu K.; Oztanir M.N.; Gul M.; Satilmis B.; Uyumlu A.B.; Kayhan B.; Genc M.; Neuroprotective effects of the new Na channel blocker rs100642 in global ischemic brain injury. Arch Med Sci 2019,15(2),467-474","journal-title":"Arch Med Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1021\/jo982287c","volume":"64","author":"Loughhead D.G.","year":"1999","unstructured":"Loughhead D.G.; Flippin L.A.; Weikert R.J.; Synthesis of mexiletine stereoisomers and related compounds via SNAr nucleophilic substitution of a Cr(CO)3-complexed aromatic fluoride. J Org Chem 1999,64(9),3373-3375","journal-title":"J Org Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-1981-29317","author":"Mitsunobu O.","year":"1981","unstructured":"Mitsunobu O.; The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981,1-28","journal-title":"Synthesis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0223-5234(00)00115-X","volume":"35","author":"Duranti A.","year":"2000","unstructured":"Duranti A.; Franchini C.; Lentini G.; Loiodice F.; Tortorella V.; De Luca A.; Pierno S.; Conte Camerino D.; Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels. Eur J Med Chem 2000,35(1),147-156","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1016\/j.tetlet.2015.05.041","volume":"56","author":"Ryan D.A.","year":"2015","unstructured":"Ryan D.A.; Okolotowicz K.J.; Mercola M.; Cashman J.R.; Stereoselective synthesis of mexiletine and structural analogs with chiral tert-butanesulfinamide. Tetrahedron Lett 2015,56(28),4195-4199","journal-title":"Tetrahedron Lett"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200504080530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181599\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200504080530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:34:35Z","timestamp":1660070075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181599\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200504080530","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}